This trial is evaluating whether Chemotherapy Agents will improve 4 primary outcomes and 19 secondary outcomes in patients with Lymphoma. Measurement will happen over the course of Predose (Day 0) and at multiple timepoints postdose (up to 60 months).
This trial requires 242 total participants across 6 different treatment groups
This trial involves 6 different treatments. Chemotherapy Agents is the primary treatment being studied. Participants will be divided into 6 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"There have been no breakthroughs for treating diffuse large B-cell lymphomas (DLBL) since the last update from the National Cancer Institute (NCI). Adult DLBL is generally diagnosed at its most advanced stage when it has metastasized to sites outside the thorax and abdomen. Treatments have improved survival rates for DLBL, but >50% of patients still do not survive 5 years after their initial diagnosis. The prognosis will vary depending upon the type of DLBL; however, patients with DLBCL treated according to current guidelines have significantly longer survival rates compared with those who did not receive therapy." - Anonymous Online Contributor
"On average, lymphoma patients receive six cycles of chemotherapy during one year. Findings from a recent study found differences between treatment options such as regimens used with different types and stages (I & II), different types of lymphomas (diffuse vs. non-diffuse), and different types of treatment methods (chemotherapy alone vs. combination therapies). The treatment regimen varies depending on how rapidly the patient's tumor grows and how fast they will develop complications from the disease. Chemotherapy agents sometimes treat the underlying cause of the disease; however, the disease can still occur even if the chemotherapy treatments are not specifically targetted at specific cancer cells. Cancer patients often receive multiple chemotherapy treatments because the effectiveness of each treatment is limited. Please see summary table below." - Anonymous Online Contributor
"The prognosis is not good for patients with newly diagnosed DLBCL, regardless of age. However, in this population, age may play an important role in survival." - Anonymous Online Contributor
"Although there may be variations between the data sources, these data suggest that about half of the patients have received one of the following regimens for current or previous relapses of DLBCL, FL, NHL, or 1012PLL. Patients who did not receive any therapy tended to have more aggressive disease characteristics. This suggests that evolution of DLBCL and NHL was slower in comparison to 1012PLL. Patients who were treated with two or more lines of chemotherapy had significantly higher survival rates compared to patients who only received one line of chemotherapy." - Anonymous Online Contributor
"Newly diagnosed diffuse large B-cell lymphoma is an aggressive and highly lethal disease. Given its rarity, aggressive multimodality therapy may not be possible. A small portion of patients respond well to chemotherapy alone, so prospective evaluation of this strategy is warranted. It remains unclear whether combined modality therapy provides any benefit." - Anonymous Online Contributor
"The median survivals for DLBCL and FL are three and two years respectively. Survival rates were comparable between the two groups. Lymphoma, diffuse, is a chronic disease with long term consequences." - Anonymous Online Contributor
"In a recent study, patients receiving chemotherapy were at similar risk of neutropenic fever compared to those not receiving chemotherapy. This finding suggests that there is no evidence supporting the hypothesis that chemotherapy causes morbidity due to infection. There was no demonstrable difference in the incidence of serious infection between patients who received chemotherapy and patients who did not receive chemotherapy." - Anonymous Online Contributor
"The authors' conclusions are that chemotherapy agents are frequently used as single agents and in combination with radiation in relapsed aggressive lymphomas. Agents commonly used in combination with chemotherapy include cyclophosphamide (Cyclo), doxorubicin (Adriamycin), vincristine (Oncovin), and prednisone. Agents commonly used in combination with radiation include chlorambucil (Leukeran), cytarabine (Ara-C), melphalan (Melf), methotrexate (MTX), and prednisolone. A greater understanding of the role of chemotherapy or agents added to radiation alone may help doctors treat cancer patients more effectively." - Anonymous Online Contributor
"Patients treated with chemotherapeutic agents commonly experience nausea, vomiting, diarrhea, fatigue, hair loss, oral mucositis, neutropenia, and mucocutaneous toxicity. Severe mucositis may result in anorexia, weight loss, and teratogenic complications. The majority of chemotherapeutic agents cause moderate to severe dermatitis, and this is more common with platinum-based compounds. Dermatitis is caused by immune-mediated mechanisms, not by direct cytotoxicity." - Anonymous Online Contributor
"Patients with non-Hodgkin's lymphoma have a very poor prognosis. However, patients with diffuse large B cell lymphoma (DLBCL) have an excellent response to therapy. The majority of DLBCL patients will respond to chemotherapy. There is currently no known biomarker that predicts response to chemotherapy in DLBCL. Thus, there is little rationale to exclude patients who may benefit from clinical trials for DLBCL." - Anonymous Online Contributor
"From the beginning of clinical trials on HDAC inhibitors, it is clear that HDACIs are active against both Hodgkin's lymphoma and DLBCL. The ultimate goal of treating Hodgkin's lymphoma with HDACIs is to achieve durable responses. Patients who have previously responded to HDACI therapy are unlikely to benefit from an additional cycle of chemotherapeutic regimens. In contrast, patients who have achieved a durable response with HDACI therapy should continue to receive HDACI therapy after they achieve complete remission. [Power] (http://www.withpower." - Anonymous Online Contributor